<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512885</url>
  </required_header>
  <id_info>
    <org_study_id>2020PI162-49</org_study_id>
    <nct_id>NCT04512885</nct_id>
  </id_info>
  <brief_title>Study of Acceptability of a New Distance-learning Tool &quot;MyFIT&quot;</brief_title>
  <acronym>MyFIT</acronym>
  <official_title>Study of the Acceptability of a New Distance-learning Tool for Functional Insulin Therapy &quot;MyFIT&quot; by Patients With Type 1 Diabetes (T1D) and by Healthcare Professionals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators developed an on-line learning tool &quot;MyFIT&quot; enabling to patients with T1D to&#xD;
      acquire the knowledge and skills for practicing functional insulin therapy from their home.&#xD;
&#xD;
      The aim of the present study is to evaluate the acceptability of this new learning modality&#xD;
      via the tool &quot;MyFIT&quot; by the patients and by the health professionnals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Actual">September 5, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>success rate</measure>
    <time_frame>2 months</time_frame>
    <description>score of the formation (80% correct answers)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>satisfaction measured by auto-questionnaire</measure>
    <time_frame>2 months</time_frame>
    <description>calculation of total score of the answers on 6-point likert scale (minimum value = 0; maximum value = 100% , higher scores mean a better outcome)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type1diabetes</condition>
  <arm_group>
    <arm_group_label>Patients with type 1 diabetes</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Health professionals</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey</intervention_name>
    <description>Survey via questionnaire</description>
    <arm_group_label>Health professionals</arm_group_label>
    <arm_group_label>Patients with type 1 diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with Type 1 diabetes followed in the department of Endocrinology,&#xD;
        diabetology and nutrition (CHRU de Nancy)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  type one diabetes on intensified insulin therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hearing loss&#xD;
&#xD;
          -  Visual problems&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Feigerlova, MD, PhD</last_name>
      <phone>00330383153412</phone>
      <email>e.feigerlova@chru-nancy.Fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>EVA FEIGERLOVA</investigator_full_name>
    <investigator_title>Assistant Professor of Endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

